作者: Gary Brooke , Tony Rossetti , Rebecca Pelekanos , Nina Ilic , Patricia Murray
DOI: 10.1111/J.1365-2141.2008.07492.X
关键词:
摘要: Mesenchymal stem cells (MSC) are being used increasingly in clinical trials for a range of regenerative and inflammatory diseases. Bone marrow is the traditional source but relatively inaccessible large volume. MSC have now been derived from tissues other than bone including placenta adipose tissue. We obtained after delivery as unable to detect any marked differences marrow-derived terms cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability. This report described our manufacturing process isolating expanding placenta-derived human their safe infusion into first patient trial program MSC.